Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

NCT02152995 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

NIH

Sponsor class

Conditions

Metastatic Thyroid Gland Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Recurrent Thyroid Gland Carcinoma
Refractory Thyroid Gland Carcinoma
Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7

Interventions

PROCEDURE: Computed Tomography
OTHER: Iodine I 124
RADIATION: Iodine I-131
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacodynamic Study
PROCEDURE: Positron Emission Tomography
DRUG: Trametinib

Sponsor

National Cancer Institute (NCI)